-two in Australia and one in North America-
BELLEVILLE, ON,
Sept. 28, 2011 /PRNewswire/ -
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a
research-based, technology-driven Canadian biopharmaceutical
company, today announced that it is launching three new products:
Cue-Mare® and
Tri-OticTM Ointment in Australia, and PERIDAN® Concentrate in
North America.
About
Cue-Mare®
Cue-Mare® is the equine
version of the Company's bovine product
Cue-Mate®, both intravaginal progesterone
delivery devices. Cue-Mare® is used for
the induction of estrous in spring transitional mares, which is
particularly important to enable early breeding. In the
non-pregnant mare, progesterone regulates the estrous cycle (heat)
or synchronizes estrous, readying the mare for insemination.
Specifically designed for equine comfort,
Cue-Mare® is the first device of its kind
approved for use in mares and offers distinct advantages over oral
and injectable progesterone products. A single administration of
Cue-Mare® provides the necessary 7- to 10-day
consistent supply of progesterone, and eliminates the need for
daily oral supplementation or repeat injections.
"Bioniche has a strong presence in the
Australian equine market with a number of product offerings,
including SETTLE®, recently introduced as
an aid in the treatment of equine endometritis and
EnhanceTM, a viscosupplementation product
for the equine athlete," said Andrew
Grant, President of Bioniche Animal Health (Global). "We
expect that the ease of administration and effectiveness of
Cue-Mare's unique presentation will be attractive features
for the equine practitioner."
It should be noted that Bayer Animal Health, a
division of Bayer Australia Limited, has an exclusive
distributorship of Bioniche's Cue-Mate® and
Pregnecol® cattle reproductive
products in Australia. Bayer
entered into an exclusive supply agreement with Angus Australia to
supply these two Bioniche products to the breed society for a
three-year period. A fixed-time artificial insemination program
using the Bioniche products has been tested in the Angus breed,
with data showing that use of the products leads to tighter calving
patterns and increased conception rates.
About
Tri-OticTMOintment
Tri-OticTM Ointment is
a canine treatment for acute and chronic Otitis externa
(inflammation of the outer ear and ear canal) that is associated
with yeast and/or bacteria susceptible to gentamicin. This
condition is prevalent in dogs, particularly in Australia where there is a population of
large, active dogs, many of which have floppy ears, making them
more susceptible.
This product represents the first in a line of
companion animal dermatological products that the Company is
introducing into the market in the coming months. Bioniche Animal
Health is increasing its presence in the companion animal market,in
preparation fora canine oncology product based on the Company's
Mycobacterial Cell Wall-DNA Complex (MCC) technology and a
botanical therapeutic (natural health) technology for treating
anxiety in dogs.
About
PERIDAN®
Concentrate
PERIDAN® Concentrate is instilled into
the abdominal cavity during surgical procedures, creating a
physical barrier between damaged tissues that helps reduce the
formation of potentially dangerous post-surgical adhesions.
"As many as 20 percent of horses that undergo
colic surgeries suffer from post-surgical adhesions and resulting
complications, which could require more surgery or even
euthanasia," said Mr. Grant. "PERIDAN® Concentrate is
a safe, effective way to reduce these risks, giving horses an
improved chance at recovery and lessening the risk of further
complications."
PERIDAN® Concentrate has been
clinically shown to reduce both the number and severity of
adhesions by 65% and 76% respectively. The product was originally
developed by ARC Medical Devices Inc. in Vancouver, British Columbia and will be
marketed as a stable, sterile, commercially available veterinary
product in the United States,
Canada and elsewhere globally by
Bioniche Animal Health. The product is manufactured at the Bioniche
manufacturing facilities in Belleville,
Ontario, Canada.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based,
technology-driven Canadian biopharmaceutical company focused on the
discovery, development, manufacturing, and marketing of proprietary
and innovative products for human and animal health markets
worldwide. The fully-integrated company employs more than 200
skilled personnel and has three operating divisions: Human Health,
Animal Health, and Food Safety. The Company's primary goal is to
develop and commercialize products that advance human or animal
health and increase shareholder value.
Bioniche Animal Health develops, manufactures
and markets veterinary biopharmaceutical products worldwide. In
North America, it has development,
manufacturing and marketing facilities in Belleville, Ontario, Canada, Athens, Georgia, U.S.A. and Pullman, Washington, U.S.A. In Australia, business is conducted from two
sites: Sydney, New South Wales, where sales and marketing,
customer support and technical service are located; and Armidale,
New South Wales, where research,
development and manufacturing facilities are located.
Bioniche Life Sciences Inc. has been named one
of the Top 50 Best Small and Medium-Sized Employers in Canada for 2010. For more information, please
visit www.Bioniche.com.
Except for historical information, this news
release may contain forward-looking statements that reflect the
Company's current expectation regarding future events. These
forward-looking statements involve risk and uncertainties, which
may cause, but are not limited to, changing market conditions, the
successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties
related to the regulatory approval process, and other risks
detailed from time to time in the Company's ongoing quarterly and
annual reporting.
SOURCE Bioniche Life Sciences Inc.